|Bid||0.00 x 1100|
|Ask||0.00 x 1400|
|Day's range||37.07 - 37.65|
|52-week range||36.91 - 58.10|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||14.32|
|Forward dividend & yield||1.75 (4.55%)|
|Ex-dividend date||26 May 2022|
|1y target est||60.17|
PARIS (Reuters) -French drugmaker Sanofi said it expected a positive boost to its third-quarter business results from movements on the currency markets, helped by the strength of the U.S. dollar since Sanofi does much of its business in the United States. Sanofi said its preliminary estimate of currency impacts on its third-quarter 2022 sales was for a boost of approximately 10% to 11%, and for a lift of around 12% and 13% on its business earnings per share (EPS). Sanofi will report third-quarter results on Oct. 28.
Availability of the Q3 2022 Memorandum for modelling purposes Paris, France – September 28, 2022 - Sanofi announced today that its Q3 2022 Memorandum for modelling purposes is available on the "Investors" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q3-results-2022 As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on variou
The FDA grants approval to Lilly's (LLY) Retevmo in advanced or metastatic solid tumors with a RET gene fusion. It converts the drug's accelerated approval in NSCLC indication to full approval.